Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
2.
Ned Tijdschr Geneeskd ; 156(25): A4458, 2012.
Article in Dutch | MEDLINE | ID: mdl-22748367

ABSTRACT

The mould Aspergillus fumigatus may develop mechanisms that confer resistance to itraconazole, voriconazole and posaconazole. In the Netherlands a dominant resistance mechanism referred to as TR/L98H is found. In A. fumigatus isolates recovered from clinical samples in Dutch hospitals the prevalence of azole resistance varied between 0.8% and 9.4%. The TR/L98H resistance mechanism probably develops in our environment, as azoles are frequently used for crop protection and material preservation. It is likely that breathing in the resistant spores of these strains from the environment leads to clinical infection. More research is needed to understand the environmental route of resistance development and to enable effective measures to prevent this occurring. Azole resistance is associated with treatment failure. Of 8 patients with azole-resistant invasive aspergillosis 7 died within 12 weeks of diagnosis. Alternative treatment regimens might include lipid-formulation of amphotericin B or a combination of voriconazole and an echinocandin, but there is little data available to support these choices. Physicians who treat patients with Aspergillus diseases should be aware of the possibility of azole resistance, also in azole-naïve patients.


Subject(s)
Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillus fumigatus/drug effects , Azoles/therapeutic use , Drug Resistance, Fungal , Azoles/pharmacology , Environmental Microbiology , Fungicides, Industrial/adverse effects , Humans , Itraconazole/pharmacology , Itraconazole/therapeutic use , Microbial Sensitivity Tests , Netherlands , Pyrimidines/pharmacology , Pyrimidines/therapeutic use , Triazoles/pharmacology , Triazoles/therapeutic use , Voriconazole
SELECTION OF CITATIONS
SEARCH DETAIL
...